Cargando…

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C

OBJECTIVES/GOALS: The effect of the Direct-Acting Antiviral (DAA) on hepatic histopathological features from patients treated for HCV has not been thoroughly evaluated. The goals of this retrospective study were to determines differences between the liver biopsies collected before and after DAA trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millian, Daniel, Saldarriaga, Omar A., Arroyave, Esteban, Wanninger, Timothy, Krishnan, Santhoshi, Rao, Arvind, Moghe, Akshata, Stevenson, Heather L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Precision Medicine/Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129449/ http://dx.doi.org/10.1017/cts.2023.321

Ejemplares similares

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
por: Saldarriaga, Omar A., et al.
Publicado: (2021)

373 Identification of potential targets for immunotherapy in a cynomolgus macaque model of Ebola virus disease
por: Wanninger, Timothy, et al.
Publicado: (2023)

Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment—Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma
por: Millian, Daniel E., et al.
Publicado: (2022)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018)

Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment
por: Ferreira, Joana, et al.
Publicado: (2023)

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
por: Welzel, Tania M., et al.
Publicado: (2019)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
por: Shoun, Aly Atef, et al.
Publicado: (2022)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

Under Disguise: A Concealed Case of Acute Hepatitis A Infection
por: Malone, Jordan C, et al.
Publicado: (2023)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
por: Aebi-Popp, Karoline, et al.
Publicado: (2016)

Macrophage infection, activation, and histopathological findings in ebolavirus infection
por: Wanninger, Timothy G., et al.
Publicado: (2022)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
por: Suenaga, Riichiro, et al.
Publicado: (2021)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

345 The Role of TCF7L2 in Hepatic Metabolic Zonation
por: Ayala, Iriscilla I., et al.
Publicado: (2023)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis
por: Santos, Ana Paula de Torres, et al.
Publicado: (2022)

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
por: Shakeri, Ahmad, et al.
Publicado: (2021)

836. Significant Elevations in CD4(+) Count, Post-treatment of Chronic Hepatitis C (HCV) with Direct Acting Antivirals (DAAs), in Human Immune Deficiency, HIV/HCV Co-infected Patients with Prolonged CD4+ lymphocytopenia, despite undetectable HIV RNA
por: Kuhn, Ryan, et al.
Publicado: (2021)

The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease
por: De Comarmond, Charles, et al.
Publicado: (2017)

Murine hepatitis virus nsp4 N258T mutants are not temperature-sensitive
por: Beachboard, Dia C., et al.
Publicado: (2013)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

“Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda
por: Gupta, Neil, et al.
Publicado: (2017)

Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy
por: Danilescu, Claudia Monica, et al.
Publicado: (2022)

Towards the characterization of the tumor microenvironment through dictionary learning-based interpretable classification of multiplexed immunofluorescence images
por: Krishnan, Santhoshi N, et al.
Publicado: (2023)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5itti86vde64aba77h1bpe6eh5